Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistence of humoral and cellular immunity after inactivated COVID-19 vaccination
ChiCTR2100051958Phase 4Completed
- Sponsor
- Beijing YouAn Hospital
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of turkovac in coronavirus disease 2019 (COVID-19), sponsored by Beijing YouAn Hospital. Primary endpoints: COVID-19 specific antibody and COVID-19 specific memory B cells. Started Oct 2021; status: completed.
02
Drugs
turkovac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100051958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051958.